Mechanism of Action and Bioactivation
Calcitriol is the end product of a complex metabolic cascade. To understand its pharmacological value, one must examine the natural two-step activation pathway of vitamin D in the body (via hydroxylation):
- Hepatic step: The initial animal-derived substrate, cholecalciferol (inactive vitamin $D_3$), is converted by the enzyme 25-hydroxylase into calcidiol (25(OH)$D_3$). This is the circulating, yet still inactive, transport form.
- Renal step: Calcidiol travels via the bloodstream to the kidneys, where the enzyme 1-alpha-hydroxylase converts it into calcitriol (1,25(OH)$_2D_3$). This substance is the true active form.
Under physiological conditions, these reactions require ultraviolet radiation (sunlight) and normal hepatic and renal function. Prescribing exogenous Calcitriol allows the patient to bypass both bioactivation steps. This is critical when a patient's synthesis of endogenous active metabolites is impaired.
Pharmacological Effects
The drug's action is closely linked to the physiological effects of parathyroid hormone (PTH). Normally, PTH stimulates the renal production of endogenous calcitriol. In turn, calcitriol duplicates and enhances the effects of PTH aimed at increasing plasma calcium concentrations.
Key mechanisms for elevating serum calcium:
- In the intestine: Mediated increase in dietary calcium absorption (one of the primary effects of active vitamin D).
- In the kidneys: Reduced urinary calcium excretion via enhanced reabsorption in the renal tubules.
- In bone tissue: Stimulation of osteoclast activity, leading to the mobilization (release) of calcium from bone stores into the systemic circulation.
Clinical Significance and Indications
The synthesis of active vitamin D metabolites in the body can decline due to three main factors: insufficient sunlight exposure, liver disease, and most commonly, renal pathologies.
Impaired renal 1-hydroxylation is a key driver in the development of osteopenia and osteoporosis. This is especially relevant in chronic kidney disease, during menopause, or with prolonged glucocorticoid therapy. In such cases, replacement therapy with exogenous calcitriol is indicated.
In pediatric populations, a deficiency of active metabolites leads to severe developmental disorders. Clinical manifestations include:
- Delayed closure of the fontanelles;
- Delayed tooth eruption;
- Skeletal deformities;
- Marked muscle weakness.
Prescription Writing Guidelines
The drug is available in oral capsules. Because doses are microscopic, extreme care must be taken with decimal placement when writing prescriptions to avoid overdose.
Available strengths: 0.00025 g and 0.005 g capsules. The standard oral dosing range is 0.00025–0.005 g.
Example prescription for the minimum dosage: Rp.: Caps. Calcitrioli 0.00025 D.t.d. N. 30 S. Take 1 capsule orally daily.